ImmvaRx, Inc. is a biotechnology company focused on immunotherapeutics. The company, founded in 1999, is advancing two product platforms that address total annual markets exceeding $30 billion: ⢠Humanized antibodies and vaccines for the diagnosis and treatment of adenocarcinoma cancers. ⢠Treatment for a broad range of Type I allergies. ImmvaRx has established an efficient pipeline for synthesis and clinical testing of its therapies. Current capabilities, combined with external capital, will enable the company to complete Phase I and II clinical trials within three years demonstrating human efficacy for the treatment of adenocarcinomas, utilizing its proprietary humanized antibodi
